Frontage Labs, a US-China CRO, Acquires Concord Biosciences

Frontage Laboratories, a Pennsylvania-Shanghai pre-clinical CRO, acquired Concord Biosciences of Cleveland, Ohio for an undisclosed price. Concord, also a pre-clinical CRO, offers expertise in pharmaceuticals, agricultural, chemical and animal health. Frontage said the acquisition will allow it to offer a complete set of services to pharma clients, while adding agricultural products to its offerings. In 2014, Hangzhou Tigermed Consulting, a clinical-stage CRO, paid $50 million for a 70% equity interest in Frontage. More details....

Stock Symbol: (SHZ: 300347)

Share this with colleagues:

Original Article: Frontage Labs, a US-China CRO, Acquires Concord Biosciences

More From BioPortfolio on "Frontage Labs, a US-China CRO, Acquires Concord Biosciences"